TY - JOUR
T1 - Temporal Trends in Acute Adrenal Insufficiency Events in Children With Congenital Adrenal Hyperplasia During 2019-2022
AU - Tseretopoulou, Xanthippi
AU - Ali, Salma R.
AU - Bryce, Jillian
AU - Amin, Nadia
AU - Atapattu, Navoda
AU - Bachega, Tania A.S.S.
AU - Baronio, Federico
AU - Ortolano, Rita
AU - Birkebaek, Niels H.
AU - Bonfig, Walter
AU - Cools, Martine
AU - Davies, Justin H.
AU - Thomas, Tessy
AU - De Vries, Liat
AU - Elsedfy, Heba
AU - Amr, Nermine H.
AU - Flueck, Christa E.
AU - Globa, Evgenia
AU - Guran, Tulay
AU - Yavas-Abali, Zehra
AU - Guven, Ayla
AU - Hannema, Sabine E.
AU - Iotova, Violeta
AU - Konrad, Daniel
AU - Lenherr-Taube, Nina
AU - Krone, Nils P.
AU - Leka-Emiri, Sofia
AU - Vlachopapadopoulou, Elpis
AU - Lichiardopol, Corina
AU - Marginean, Otilia
AU - Markosyan, Renata
AU - Neumann, Uta
AU - Niedziela, Marek
AU - Banaszak-Ziemska, Magdalena
AU - Phan-Hug, Franziska
AU - Poyrazoglu, Sukran
AU - Probst-Scheidegger, Ursina
AU - Randell, Tabitha
AU - Russo, Gianni
AU - Salerno, Mariacarolina
AU - Seneviratne, Sumudu
AU - Shnorhavorian, Margarett
AU - Thankamony, Ajay
AU - Tadokoro-Curraro, Rieko
AU - Van Den Akker, Erica
AU - Van Eck, Judith
AU - Vieites, Ana
AU - Wasniewska, Malgorzata
AU - Ahmed, S. Faisal
N1 - Publisher Copyright:
© 2024 The Author(s). Published by Oxford University Press on behalf of the Endocrine Society.
PY - 2024/10
Y1 - 2024/10
N2 - Background: It is unclear whether targeted monitoring of acute adrenal insufficiency (AI) related adverse events (AE) such as sick day episodes (SDEs) and hospitalization rate in congenital adrenal hyperplasia (CAH) is associated with a change in the occurrence of these events. Aim: Study temporal trends of AI related AE in the I-CAH Registry. Methods: In 2022, data on the occurrence of AI-related AE in children aged <18 years with 21-hydroxylase deficiency CAH were compared to data collected in 2019. Results: In 2022, a total of 513 children from 38 centers in 21 countries with a median of 8 children (range 1-58) per center had 2470 visits evaluated over a 3-year period (2019-2022). The median SDE per patient year in 2022 was 0 (0-2.5) compared to 0.3 (0-6) in 2019 (P =. 01). Despite adjustment for age, CAH phenotype and duration of study period, a difference in SDE rate was still apparent between the 2 cohorts. Of the 38 centers in the 2022 cohort, 21 had also participated in 2019 and a reduction in SDE rate was noted in 13 (62%), an increase was noted in 3 (14%), and in 5 (24%) the rate remained the same. Of the 474 SDEs reported in the 2022 cohort, 103 (22%) led to hospitalization compared to 299 of 1099 SDEs (27%) in the 2019 cohort (P =. 02). Conclusion: The I-CAH Registry can be used for targeted monitoring of important clinical benchmarks in CAH. However, changes in reported benchmarks need careful interpretation and longer-term monitoring.
AB - Background: It is unclear whether targeted monitoring of acute adrenal insufficiency (AI) related adverse events (AE) such as sick day episodes (SDEs) and hospitalization rate in congenital adrenal hyperplasia (CAH) is associated with a change in the occurrence of these events. Aim: Study temporal trends of AI related AE in the I-CAH Registry. Methods: In 2022, data on the occurrence of AI-related AE in children aged <18 years with 21-hydroxylase deficiency CAH were compared to data collected in 2019. Results: In 2022, a total of 513 children from 38 centers in 21 countries with a median of 8 children (range 1-58) per center had 2470 visits evaluated over a 3-year period (2019-2022). The median SDE per patient year in 2022 was 0 (0-2.5) compared to 0.3 (0-6) in 2019 (P =. 01). Despite adjustment for age, CAH phenotype and duration of study period, a difference in SDE rate was still apparent between the 2 cohorts. Of the 38 centers in the 2022 cohort, 21 had also participated in 2019 and a reduction in SDE rate was noted in 13 (62%), an increase was noted in 3 (14%), and in 5 (24%) the rate remained the same. Of the 474 SDEs reported in the 2022 cohort, 103 (22%) led to hospitalization compared to 299 of 1099 SDEs (27%) in the 2019 cohort (P =. 02). Conclusion: The I-CAH Registry can be used for targeted monitoring of important clinical benchmarks in CAH. However, changes in reported benchmarks need careful interpretation and longer-term monitoring.
UR - http://www.scopus.com/inward/record.url?scp=85203970625&partnerID=8YFLogxK
U2 - 10.1210/jendso/bvae145
DO - 10.1210/jendso/bvae145
M3 - Article
C2 - 39258010
AN - SCOPUS:85203970625
SN - 2472-1972
VL - 8
JO - Journal of the Endocrine Society
JF - Journal of the Endocrine Society
IS - 10
M1 - bvae145
ER -